Aerosolized antibiotics in cystic fibrosis: An update

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Inhaled antibiotic therapy, targeting Pseudomonas aeruginosa, is a fundamental component of cystic fibrosis (CF) management. Tobramycin inhalation solution (TIS) was approved in the United States (US) in 1998. Subsequent research efforts focused on developing products with a reduced treatment time burden. Aztreonam for inhalation solution (AZLI), administered via a more efficient nebulizer than TIS, was approved in the US in 2010. Dry powder for inhalation (DPI) formulations provide alternatives to nebulized therapy: tobramycin powder for inhalation (also known as TIP™) was approved in the US in 2013, and colistimethate sodium DPI received European approval in 2012. Other aerosolized antibiotics and regimens combining inhaled antibiotics are in development. Inhaled antibiotic rotation (e.g., TIS alternating with AZLI) is an important concept being actively tested in CF.

Original languageEnglish (US)
Pages (from-to)305-314
Number of pages10
JournalExpert Review of Respiratory Medicine
Volume8
Issue number3
DOIs
StatePublished - Jun 2014
Externally publishedYes

Fingerprint

Cystic Fibrosis
Inhalation
Tobramycin
Anti-Bacterial Agents
Powders
Aztreonam
Nebulizers and Vaporizers
Pseudomonas aeruginosa
Therapeutics
Research

All Science Journal Classification (ASJC) codes

  • Immunology and Allergy
  • Pulmonary and Respiratory Medicine
  • Public Health, Environmental and Occupational Health

Cite this

@article{caf521310e0e4e3d8900c5c63c065645,
title = "Aerosolized antibiotics in cystic fibrosis: An update",
abstract = "Inhaled antibiotic therapy, targeting Pseudomonas aeruginosa, is a fundamental component of cystic fibrosis (CF) management. Tobramycin inhalation solution (TIS) was approved in the United States (US) in 1998. Subsequent research efforts focused on developing products with a reduced treatment time burden. Aztreonam for inhalation solution (AZLI), administered via a more efficient nebulizer than TIS, was approved in the US in 2010. Dry powder for inhalation (DPI) formulations provide alternatives to nebulized therapy: tobramycin powder for inhalation (also known as TIP™) was approved in the US in 2013, and colistimethate sodium DPI received European approval in 2012. Other aerosolized antibiotics and regimens combining inhaled antibiotics are in development. Inhaled antibiotic rotation (e.g., TIS alternating with AZLI) is an important concept being actively tested in CF.",
author = "Fiel, {Stanley B.}",
year = "2014",
month = "6",
doi = "10.1586/17476348.2014.896205",
language = "English (US)",
volume = "8",
pages = "305--314",
journal = "Expert Review of Respiratory Medicine",
issn = "1747-6348",
publisher = "Expert Reviews Ltd.",
number = "3",

}

Aerosolized antibiotics in cystic fibrosis : An update. / Fiel, Stanley B.

In: Expert Review of Respiratory Medicine, Vol. 8, No. 3, 06.2014, p. 305-314.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Aerosolized antibiotics in cystic fibrosis

T2 - An update

AU - Fiel, Stanley B.

PY - 2014/6

Y1 - 2014/6

N2 - Inhaled antibiotic therapy, targeting Pseudomonas aeruginosa, is a fundamental component of cystic fibrosis (CF) management. Tobramycin inhalation solution (TIS) was approved in the United States (US) in 1998. Subsequent research efforts focused on developing products with a reduced treatment time burden. Aztreonam for inhalation solution (AZLI), administered via a more efficient nebulizer than TIS, was approved in the US in 2010. Dry powder for inhalation (DPI) formulations provide alternatives to nebulized therapy: tobramycin powder for inhalation (also known as TIP™) was approved in the US in 2013, and colistimethate sodium DPI received European approval in 2012. Other aerosolized antibiotics and regimens combining inhaled antibiotics are in development. Inhaled antibiotic rotation (e.g., TIS alternating with AZLI) is an important concept being actively tested in CF.

AB - Inhaled antibiotic therapy, targeting Pseudomonas aeruginosa, is a fundamental component of cystic fibrosis (CF) management. Tobramycin inhalation solution (TIS) was approved in the United States (US) in 1998. Subsequent research efforts focused on developing products with a reduced treatment time burden. Aztreonam for inhalation solution (AZLI), administered via a more efficient nebulizer than TIS, was approved in the US in 2010. Dry powder for inhalation (DPI) formulations provide alternatives to nebulized therapy: tobramycin powder for inhalation (also known as TIP™) was approved in the US in 2013, and colistimethate sodium DPI received European approval in 2012. Other aerosolized antibiotics and regimens combining inhaled antibiotics are in development. Inhaled antibiotic rotation (e.g., TIS alternating with AZLI) is an important concept being actively tested in CF.

UR - http://www.scopus.com/inward/record.url?scp=84901068785&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901068785&partnerID=8YFLogxK

U2 - 10.1586/17476348.2014.896205

DO - 10.1586/17476348.2014.896205

M3 - Review article

C2 - 24838090

AN - SCOPUS:84901068785

VL - 8

SP - 305

EP - 314

JO - Expert Review of Respiratory Medicine

JF - Expert Review of Respiratory Medicine

SN - 1747-6348

IS - 3

ER -